UBS released a research report stating that BUD APAC (01876) reported Q3 2025 revenue and adjusted EBITDA of $1.555 billion and $438 million, respectively, down 8.8% and 8.6% year-on-year. These figures were 1-3% below the bank's expectations but broadly in line with market consensus.
The bank lowered its 2025–2027 earnings forecasts for BUD APAC by 7–9%, citing persistent weakness in the Chinese market and limited visibility for Q4, with recovery now expected to be delayed until 2026.
Despite the downward revision, UBS maintained a "Buy" rating, citing premiumization trends in the home consumption channel, attractive valuation, and strong cash reserves sufficient to support stable dividends in 2025. The target price was reduced from HK$9.07 to HK$8.75.